Get the Stockscreener App
9.14
2.70%
0.24
After Hours:
9.15
0.010
+0.11%
89 Bio Inc stock is traded at $9.14, with a volume of 344.97K.
It is up +2.70% in the last 24 hours and up +16.14% over the past month.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
See More
Previous Close:
$8.90
Open:
$8.93
24h Volume:
344.97K
Relative Volume:
0.52
Market Cap:
$1.05B
Revenue:
-
Net Income/Loss:
$-174.61M
P/E Ratio:
-4.3318
EPS:
-2.11
Net Cash Flow:
$-165.54M
1W Performance:
+14.54%
1M Performance:
+16.14%
6M Performance:
+12.29%
1Y Performance:
+19.79%
1-Day Range:
$8.77
$9.18
1-Week Range:
$7.80
$9.50
52-Week Range:
$7.00
$16.63
89 Bio Inc Stock (ETNB) Company Profile
Name
89 Bio Inc
Sector
Industry
Phone
(415) 432-9270
Address
142 SANSOME STREET, SAN FRANCISCO, CA
Compare ETNB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ETNB
89 Bio Inc
|
9.14 | 1.05B | 0 | -174.61M | -165.54M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
89 Bio Inc Stock (ETNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-24 | Resumed | BofA Securities | Buy |
| Jan-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-10-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-23 | Initiated | UBS | Buy |
| Jun-13-23 | Initiated | Evercore ISI | Outperform |
| May-12-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-20-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-21 | Resumed | Cantor Fitzgerald | Overweight |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-20 | Initiated | Raymond James | Strong Buy |
| Sep-25-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-23-20 | Initiated | BTIG Research | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Dec-09-19 | Initiated | BofA/Merrill | Neutral |
| Dec-09-19 | Initiated | Oppenheimer | Outperform |
| Dec-09-19 | Initiated | RBC Capital Mkts | Outperform |
| Dec-09-19 | Initiated | SVB Leerink | Outperform |
View All
89 Bio Inc Stock (ETNB) Latest News
89bio to Participate in the 7th Annual Evercore HealthCONx Conference - The Manila Times
89bio to Present at Evercore HealthCONx Conference, Showcasing Pipeline Updates | ETNB Stock News - StockTitan
Insider Buying: Rohan Palekar Acquires 10,000 Shares of 89bio In - GuruFocus.com
Rohan Palekar Purchases 10,000 Shares of 89bio, Inc. (NASDAQ:ETNB) Stock - MarketBeat
89bio, Inc. (NASDAQ:ETNB) Stock Position Lifted by Westfield Capital Management Co. LP - MarketBeat
89bio CEO Rohan Palekar buys $83,500 in company stock By Investing.com - Investing.com South Africa
89bio CEO Rohan Palekar buys $83,500 in company stock - Investing.com India
Non-alcoholic Steatohepatitis (NASH) Treatment Market 2032: Clinical Trials, Medication, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight - The Globe and Mail
Silvercorp Metals Inc (SVM-T) QuotePress Release - The Globe and Mail
89Bio Inc. Reports Q3 2024 Financial Results - TipRanks
89bio drops 2%, prices $125M stock offering - MSN
RA CAPITAL MANAGEMENT, L.P. Increases Stake in 89bio Inc - GuruFocus.com
89bio Inc.’s $125 Million Common Stock Offering - Global Legal Chronicle
Finance Watch: Biopharma Stocks Sink On RFK Jr. Nomination To Head HHS - News & Insights
Syncona building Slingshot incubator; Trace launches with $101M - BioCentury
89bio reports potential MASH treatment progress By Investing.com - Investing.com Canada
89bio reports potential MASH treatment progress - Investing.com
89bio's Pegozafermin Shows Promising Results in Advanced MASH Treatment Trial | ETNB Stock News - StockTitan
89bio, Inc. announces public offering and warrant issuance By Investing.com - Investing.com Nigeria
89bio, Inc. announces public offering and warrant issuance - Investing.com
Janus Henderson Group PLC's Strategic Acquisition in 89bio Inc - GuruFocus.com
FY2024 EPS Estimates for 89bio Lowered by Cantor Fitzgerald - MarketBeat
HC Wainwright Issues Pessimistic Estimate for 89bio Earnings - MarketBeat
BioXcel Q3 Revenue Drops 37%, but Net Loss Narrows Significantly to $13.7M | BTAI Stock News - StockTitan
89bio announces $100 million public stock offering - Investing.com India
SEC Form 424B5 filed by 89bio Inc. - Quantisnow
89bio announces $100 million public stock offering By Investing.com - Investing.com Australia
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Let Poetry Illuminate China's Green City -- The 2nd Nanning International Poetry Week Opens - The Manila Times
89bio Raises $125M in Upsized Public Offering at $8.50 Per Share | ETNB Stock News - StockTitan
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire Inc.
ETNB89bio, Inc. Latest Stock News & Market Updates - StockTitan
89bio announces proposed underwritten public offering of common stock and pre-funded warrants - MSN
BioLife Solutions Surges 30% in Q3 Revenue, Slashes Net Loss by 89% | Earnings Report | BLFS Stock News - StockTitan
89bio Launches $100M Public Offering to Advance Pegozafermin Development | ETNB | ETNB Stock News - StockTitan
GLP-1s push into MASH as semaglutide 2.4 mg hits endpoints - BioWorld Online
89bio Inc (ETNB) Quarterly 10-Q Report - Quartzy
89bio, Inc. (NASDAQ:ETNB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
HC Wainwright Reaffirms Buy Rating for 89bio (NASDAQ:ETNB) - MarketBeat
FY2028 Earnings Estimate for 89bio Issued By Leerink Partnrs - MarketBeat
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Raymond James Issues Pessimistic Forecast for 89bio (NASDAQ:ETNB) Stock Price - MarketBeat
Block Inc (SQ-N) QuotePress Release - The Globe and Mail
89bio Reports Third Quarter 2024 Financial Results and Corporate UpdatesSAN FRANCISCO, November 7, 2024 (GLOBE NEWSWIRE) – On November 7, 2024, 89bio, Inc. (NASDAQ: ETNB), a clinical-stage biopharmaceutical company focusing on innovativ - Defense World
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates - The Manila Times
89bio Inc (ETNB) Has A Gold Mine On Its Hands - Stocks Register
Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace
Harbor Capital Advisors Inc. Purchases 142,032 Shares of 89bio, Inc. (NASDAQ:ETNB) - MarketBeat
89bio to Participate in the UBS Global Healthcare Conference - The Manila Times
89bio to Present at UBS Global Healthcare Conference: Key Investor Updates Coming | ETNB Stock News - StockTitan
Lyft Inc Cl A (LYFT-Q) QuotePress Release - The Globe and Mail
89 Bio Inc Stock (ETNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
89 Bio Inc Stock (ETNB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Le-Nguyen Quoc | See Remarks |
Oct 30 '24 |
Sale |
8.12 |
27,955 |
226,995 |
187,796 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):